Terry

Sanofi Buys Vigil In $470 Million Deal For Alzheimer’s TREM2 Drug

UroGen Draws A Split Adcom Panel Vote For Bladder Cancer Drug UGN-102

Pfizer Wants To Throw Its Hat Into The Ring With Up To $6 Billion 3SBio Deal

Prime Medicine Not Keen On PM359 Advancement Despite Initial Data

CRISPR Scores Win For CTX310 Targeting Cholesterol Patients

Vertex Pauses Study Of VX-522 For Patients With Cystic Fibrosis

Biomea Takes Workforce Reduction Play Of 35% For Realignment Plans

Pliant Takes Late-Stage Route After Bexotegrast Issue And Slashes Workforce by 45%

Immunic Might Still Have Path Forward In PMS After Primary Endpoint Miss

Abeona Receives FDA Approval Of ZEVASKYN Marking A First

Positive Sasanlimab Data From Pfizer Could Bring New Medicine For High-Risk Bladder Cancer

Caribou Cuts Workforce And Puts Focus To lead Oncology Candidates

Genentech Aims For DECODE Platform From Repertoire In $765 Million Deal

Bristol-Myers Squibb Fails Phase 3 Study With Cobenfy

In Flight To Enact Strategic Alternatives, Tempest Cuts 80% of its Workforce

Eli Lilly’s Orforglipron Delivers Efficacy Similar To That Of Injectable GLP-1 Drugs

Despite Primary Endpoint Falling Short, Sanofi Moving Amlitelimb Forward

Mural Oncology Mulls Strategic Alternatives After Latest Failure With IL-2 Candidate

Pfizer Shelves GLP-1 Obesity Drug After Liver Injury In A Patient

Annexon’s C1q Targeting Of Complement System Could Bring About First Treatment For GBS

Scroll to Top